Sanofi confirmed advanced regulator talks on Phase 3 timing for its COVID-19/flu combination vaccine, triggering a USD 125 million milestone on trial start.
Quarterly results and revenue mix
Novavax swung to a net loss of USD 53.39 million, or USD 0.32 a share, in the quarter ended June 30, 2026.
Revenue fell 76.29% to USD 56.7 million, led by licensing, royalties and other dropping 83.45% to USD 37.84 million.
Product sales rose 75.78% to USD 18.85 million, driven by higher supply sales as Nuvaxovid sales fell to no revenue.
NVAX•
